Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
(Q28256478)
scientific article
scientific article
Language:
| (P31) |
(Q13442814)
|
||||||||||||||||||||||||||||||
| (P50) |
(Q109984365)
|
||||||||||||||||||||||||||||||
| (P304) |
5305-13
|
||||||||||||||||||||||||||||||
| (P407) |
(Q1860)
|
||||||||||||||||||||||||||||||
| (P433) |
23
|
||||||||||||||||||||||||||||||
| (P478) |
23
|
||||||||||||||||||||||||||||||
| (P577) |
Wednesday, August 10, 2005
|
||||||||||||||||||||||||||||||
| (P921) |
(Q181600)
(Q323936)
|
||||||||||||||||||||||||||||||
| (P1433) |
(Q400292)
|
||||||||||||||||||||||||||||||
| (P1476) |
"Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas" (language: en)
|
||||||||||||||||||||||||||||||
| (P2093) |
Howard A Burris
Herbert I Hurwitz
Afshin Dowlati
Kimberly L Blackwell
Bert O'Neil
Paul K Marcom
Matthew J Ellis
Beth Overmoyer
Suzanne F Jones
Jennifer L Harris
Deborah A Smith
Kevin M Koch
Andrew Stead
Steve Mangum
Neil L Spector
|